Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis

SinnoVex is a drug from the group of bioanalogues of interferon beta-1a for intramuscular administration, which has moderate efficacy in reducing clinical exacerbations of multiple sclerosis (MS), which is most pronounced in the initial treatment of relapsing-remitting MS (RRMS) with low or moderate disease activity.

Objective: to analyze the experience with the use of the drug SinnoVex in several parallel studies in the Russian population of patients with RRMS.

Material and methods. We analyzed the results of three retrospective post-marketing clinical trials, in which we compared the efficacy and safety of the use of interferon beta-1a for once-weekly intramuscular administration under the trade name SinnoVex in the treatment of the Russian population of patients with RRMS with other MS disease-modifying treatments (DMTs), in particular with high-dose interferons beta-1a and interferons beta-1b for subcutaneous administration. The total number of patients who received therapy with SinnoVex was 235 subjects. The efficacy of the therapy was assessed using the following indicators: average annual frequency of exacerbations, MRI activity, achievement of the NEDA-3 indicator. The safety of the therapy was evaluated based on the occurrence of adverse events (AEs) and their severity as well as the frequency of discontinuation of the drug.

Results. Based on the results of the studies presented, no statistically significant differences in the clinical efficacy or tolerability of the intramuscularly administered SinnoVex preparation compared to other drugs of the interferon beta group were found. The spectrum and severity of AEs were in line with expectations; no unexpected AEs were observed.

Conclusion. Among the important advantages of the drug are the relatively rare intramuscular injections and rare local skin AEs after injections, which significantly increase the benefit of the drug in young patients. In this regard, SinnoVex is most commonly used as an initial drug as part of an escalation approach to the treatment of RRMS and then needs to be replaced by more highly effective firstor second-line DMTs if efficacy is insufficient.

1. Lee JY, Taghian K, Petratos S. Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? Acta Neuropathol Commun. 2014 Aug 27;2:97. doi: 10.1186/s40478-014-0097-7

2. Correale J, Marrodan M, Ysrraelit MC. Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. Biomedicines. 2019 Feb 20;7(1):14. doi: 10.3390/biomedicines7010014

3. Vartanian T, Li Y, Zhao M, Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med. 1995 Nov;1(7):732-43.

4. Zhao X, Jacob C. Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis. Int J Mol Sci. 2023 Mar 28;24(7):6373. doi: 10.3390/ijms24076373

5. Boyko AN, Khabirov FA, editors. Clinical picture, diagnosis and treatment of multiple sclerosis: a guide for doctors. Kazan: Medicine; 2010. P. 88 (In Russ.).

6. O'Connor PW, Oh JW. Disease-modifying agents in multiple sclerosis. In: Goodin DS, ed. Handbook of clinical neurology. Vol. 122 (3rd series): Multiple sclerosis and related disorders. Elsevier B. V.; 2014. P. 465-501.

7. EMEA/CHMP/437/04 Rev 1 (30 Apr 2015). Guideline on similar biological medicinal products. Available at: www.ema.europa.eu/

8. EMEA/CHMP/BMWP/652000/20100 (01 Sep 2013). Guideline on similar biological medicinal products containing interferon beta. Available at: http://www.ema.europa.eu/

9. WHO. Expert Committee on Biological Standardization, Geneva, 19 to 23 October 2009. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available at: http://www.who.int/

10. Khabirov FA, Khaibullin TI, Granatov EV, et al. The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):18-26. doi: 10.17116/jnevro20181183118-26 (In Russ.).

11. Borets OG, Davydovskaya MV, Demina TL, et al. Experience of using interferon β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(2-2):51-6. doi: 10.17116/jnevro20151152251-56 (In Russ.).

12. Kasatkin DS, Spirin NN, Boiko AN, et al. The results of an open prospective study of β-interferon biosimilars (an Yaroslavl' cohort). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2-2):68-73. doi: 10.17116/jnevro20161162268-73 (In Russ.).

13. Khabirov FA, Averyanova LA, Babicheva NN, et al. Analysis of the effectiveness and safety of interferon beta-1a biosimilar for intramuscular injection in the treatment of multiple sclerosis. Sovremennaya meditsina: nevrologiya/psikhiatriya = Modern Medicine: Neurology/Psychiatry. 2016;1(1):21-4 (In Russ.).

14. Bakhtiiarova KZ, Bragina OV, Vlasov YaV, et al. Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(8):39-45 (In Russ.). 19.04.2024/02.07.2024/03.07.2024